The aim of the study was to determine treatment results in patients with retroperitoneal sarcomas, especially as respects the value of combined therapy. Material and methods. The study group included 37 patients with retroperitoneal sarcomas who underwent treatment at the Department of Oncological Surgery, Oncology Center in Gliwice during the period between 1992 and 2005. The study group included 25 women and 12 men, aged between 21 and 68 years (mean age -56.2 years). Adjuvant therapy after the operation was performed in the case of 15 patients. Nine received adjuvant teleradiotherapy (RT) at an average dose of 47.5 Gy (one patient after a non-resective procedure). Four received intraoperative brachytherapy (BT) at a dose of 15.8 Gy in combination with postoperative teleradiotherapy at a dose of 39 Gy. One patient was subjected to intraoperative brachytherapy. One female patient received adjuvant chemotherapy (Iphosphamid + Adriamycin). Results. The cumulative five-year total survival period of the analysed group was 40.7% according to Kaplan-Meier's method. Twenty patients died and four were diagnosed with recurrence, while 13 continue to live without recurrence. The type of resection had a significant effect on total survival (p=0.013): the five-year survival after radical procedures was 52.1%. We observed no five-year survivals after nonradical procedures. In order to determine the efficacy of combined treatment, patients who underwent to radical therapy were divided into three groups: patients without adjuvant therapy (group 1: 22 patients, 62.9%), patients subjected to adjuvant RT and BT therapy after the primary operation (group II: 5 patients, 14.25%), and patients who underwent the above-mentioned treatments after surgery, due to recurrence (group III: 8 patients, 22.85%). The total five-year survival in group I was 34.8%, in group II, 80%, and in group III, 72.9%. These differences were statistically insignificant (p=0.440). These results were probably influenced by the small number of patients, considering particular groups. Conclusions. 1. The most important prognostic factor in the treatment of retroperitoneal sarcomas is surgical margine type surgical margin. 2. Adjuvant radiotherapy, especially in combination with intraoperative brachytherapy, seems to be a promising method for the management of retroperitoneal sarcomas, and improves treatment results. 3. Treatment of retroperitoneal sarcomas should be undertaken in specialized centers adequately prepared for combined therapy.
on their histological structure, retroperitoneal sarcomas are highly differentiated neoplasms: liposarcomas are most often observed, followed by leiomyosarcomas, Schwannomas and others. Retroperitoneal sarcomas usually grow slowly, and clinical symptoms develop when the neoplasm compresses or infiltrates abdominal cavity organs. More than 50% of the abovementioned neoplasms exceed 20 cm in diameter upon diagnosis (1) (2) (3) (4) (5) (6) (7) .
Treatment of retroperitoneal sarcomas consists of radical excision of the tumor, which is considered to be the most important prognostic factor. However, neoplasm-free margins are difficult to obtain, due to the size of the tumor and anatomy of the retroperitoneal space (3, 7, 8, 9) . It is difficult or impossible to determine negative margins within the retroperitoneal space, so most authors consider differences between R0 and R1 resections to be insignificant.
The recommended radical surgical excision in cases of retroperitoneal sarcoma often involves the removal of abdominal cavity organs such as the kidneys, small or large bowel loops, spleen and other structures (4, 7, 10) .
Cytoreductive operations are generally considered non-beneficial, although in selected cases these palliative procedures prolong patient survival (11) .
In spite of progress in diagnosis, development of surgical techniques and the introduction of aggressive therapeutic methods, retroperitoneal sarcomas tend to recur even in cases of complete resections (70% recur). Inoperable local recurrences are frequently responsible for patient death (3, 12, 13) .
Thus, the most important challenge when treating retroperitoneal sarcoma is prevention of local recurrences. In addition radical surgery, one should consider appropriate adjuvant therapy.
Teleradiotherapy is associated with many challenges when used to treat retroperitoneal tumors, due to possible post-radiation damage of vital organs. Additionally, difficulties in the identification and delineation of the area requiring radiation after radical render administration of the desired, full radiation dose impossible (2, 12, 13, 14) .
Chemotherapy is usually ineffective in the treatment of sarcomas. Selected centers apply chemotherapy in combination with radiotherapy during clinical trials (15) .
Promising results have been published regarding the use of intraoperative brachytherapy and intraoperative teleradiotherapy following radical excision of the sarcoma, usually in combination with perioperative teleradiotherapy (7, 14, (16) (17) (18) (19) (20) .
It is possible that radiation therapy in the operating room will supplement surgical treatment to better protect vital organs.
MATERIAL AND METHODS
During the period between 1992 and 2005, 37 patients (25 women and 12 men) were treated at the Department of Oncological Surgery, Oncology Center in Gliwice. Patient ages ranged between 21 and 68 years (median 56.2 years). Seventeen (45.9%) patients were initially treated at the Institute of Oncology, while 20 (54.1%) were admitted to our department due to neoplastic recurrence. All patients underwent surgical treatment. The tumor diameters ranged between 5 and 50 cm (mean 18.25 cm, median 15 cm). Histopathological examination demonstrated nine types of sarcomas, which were predominantly liposarcomas (17, 45.9%) followed by leiomyosarcomas (10, 27%; see tab. 1).
The histological stages of malignancy were as follows: G1 in 11 patients, G2 in 10 and G3 in six. In nine cases the degree of malignancy was unknown. In 12 patients, abdominal organs were excised during the initial operation and in seven during the second (tab. 2). Most often the following organs were removed: kidneys, large colon, stomach, and spleen, as well as part of the liver, pancreatic tail, suprarenal glands and diaphragm. Four patients had more than one organ excised. Five patients were subjected to a third operation, due to non-resective changes.
Fifteen patients underwent to adjuvant therapy. Nine received adjuvant teleradiotherapy Value of combined treatment of retroperitoneal sarcomas blications, the influence of the type of resection on survival was significant (p=0.013).
The three-year survival rate for cases of radical operations (R0, R1) was to 77.2%, but it was 26.7% for cases with non-radical operations (R2, explorative laparotomies). The five-year survival rate after radical procedures was 52.1%, but was nonexistent after nonradical procedures. All patients who underwent only explorative laparotomy died within 1.5 years.
To determine the efficacy of adjuvant therapy, patients were divided into three groups:
I. Patients without adjuvant therapy (22 patients, 59.5%).
II. Patients who received to adjuvant therapy after the primary operation (5 patients, 13.5%).
III. Patients who underwent adjuvant therapy after surgery due to neoplastic recurrence (10 patients, 27%).
at an average dose of 47.5 Gy and four were treated with intraoperative brachytherapy (Iryd 192) at a dose of 15.8 Gy combined with postoperative teleradiotherapy at an average dose of 39 Gy. One patient only received intraoperative brachytherapy and one female patient underwent to adjuvant chemotherapy (Iphosphamid + Adriamycin).
The effectiveness of therapy was calculated as the probability of survival evaluated on the basis of Kaplan-Meier's method (21) . The logrank test was used for the comparison of survival curves. p=0.05 was considered statistically significant.
RESULTS
The five-year survival across the entire analysed group was 40.7% ( fig. 1 ).
Treatment results depended on the type of the operation. Consistent with other pu- 
Group I
Patients without adjuvant therapy constituted the largest group, with 22 patients (59.5%). Radical treatment (R0 and R1 resections) was performed in 15 patients (68.2%). In the remaining 7 cases (31.8%), curative resections were not possible because of the stage of the neoplasm as well as infiltration of vital abdominal cavity organs.
Local sarcoma recurrence was observed in 10 subjects (66.7%) an average of 25.6 months after the primary operation (range between 5.1 and 68.8 months) in cases of radical treatment. In the case of one patient, liver metastases were diagnosed three months after the operation.
From group I, 15 patients (68.2%) died. All patients subjected to non-radical operations died (7 pts.) an average of 17.5 months after beginning treatment (range between 9 and 38.4 months).
Of the patients subjected to radical treatment, eight died after an average period of 30.2 months (ranging between 7.1 and 71.3 months) following the beginning of treatment. Excepting the patient with liver metastases, all died from neoplastic recurrence. Seven patients remained alive following radical treatment for an average of 41.4 months (ranging between 22.5 and 109 months), including three with neoplastic recurrence.
Group II Adjuvant treatment, in the form of teleradiotherapy after primary surgery, was performed in five patients. Two additionally underwent intraoperative brachytherapy. Postoperative radiotherapy consisted of doses of 45, 46.4 and 62 Gy. Intraoperative brachytherapy (HDR) using Ir 192 at a dose of 15 Gy was supplemented by adjuvant teleradiotherapy at doses of 45 Gy and 50.4 Gy.
One patient died 9.9 months after the primary operation without symptoms of recurrence. The remaining patients are alive without sarcoma recurrence. Total survival time averaged of 54.6 months (ranging between 9.9 and 89.3 months) (tab. 4).
Group III
Ten patients required adjuvant therapy after surgery due to neoplastic recurrence. One One patient who underwent only radical surgery remains alive without recurrence (19.8 months).
Out of eight patients who underwent adjuvant teleradiotherapy or teleradiotherapy and intraoperative brachytherapy, four were diagnosed with unresectable local recurrence after an average of 27.1 months (ranging between 3.3 and 58.7 months). One patient was additionally diagnosed with distant metastases. Four patients died after an average of 44.9 months (ranging between 12.2 and 51.8 months). Five remained alive after an average of 67 months (ranging between 19.8 and 130.6 months), including one with neoplastic recurrence.
Of the 37 investigated patients, 20 died, 4 remain alive with neoplastic recurrence, and 13 are free of recurrence.
To determine the efficacy of adjuvant treatment, we compared the total survival time for patients who received radical surgery without adjuvant radiotherapy (group I), with that of patients who underwent curative resection followed by adjuvant therapy (RT+BT) following the primary (group II) or secondary (group III) surgical intervention ( fig. 3) . The five-year survival in group I was to 34.8%, in group II 80%, and group III 72.9%. These differences were statistically insignificant. Due to the small number of patients and short observation period we did not analyse the differences between total and asymptomatic survival in the cases of patients who underwent to various adjuvant therapeutic methods (teleradiotherapy vs teleradiotherapy + intraoperative brachytherapy).
Complications
During the perioperative period three patients died. These patients were diagnosed with highly advanced, inoperable tumor recurrence. One patient died because of sepsis following two re-operations, due to intestinal fistula presence. Another patient with a non-resectable tumor died because of massive digestive tract hemorrhage after explorative laprotomy. The third patient died of renal insufficiency after excision of his remaining kidney due to sarcoma infiltration.
Wound infections were the most common postoperative complication, and were observed in five patients. One patient was diagnosed with a colon fistula requiring reoperation. Ad- Fig. 3 . Total survival after radical surgical procedures relevant to adjuvant therapy ditionally, during the postoperative period we noted pneumonia and arrhythmias requiring cardiological treatment. Digestive tract symptoms (abdominal pain, loose stools) were observed in four patients subjected to adjuvant teleradiotherapy but these symptoms regressed after conservative treatment. In case of one patient, radiotherapy had to be interrupted for a period of two weeks. Another patient undergoing intraoperative brachytherapy developed a distant postradiation reaction in the form of ejaculatory dysfunction and uretero-stenosis with urinary retention.
Local recurrence (14 cases 60.9%) and multifocal peritoneal cavity dissemination (6 cases, 26.1%) were responsible for tumor non-resectability and patient death, including two (8.7%) cases of distant liver metastases. One patient (4.3%) was diagnosed with distant metastases and peritoneal cavity dissemination.
DISCUSSION
Radical surgical treatment combined with adjuvant radiotherapy is an acknowledged method for the management of limb sarcomas. This method is widely accepted and has improved treatment results. In the 1970's the fiveyear survival was 30%, but currently ranges between 70-80% in leading centers (1, 22) .
The results of retroperitoneal sarcoma treatment are much worse due to their rarity and histological diversity, which complicate the biological understanding of these tumors and in- hibit the development of effective therapeutic procedures (6, 12) . Since failure of retroperitoneal sarcoma treatment is usually associated with local recurrence, and less frequently distant metastases (3, 8, 10, 20, 23) , the surgical margin seems to be the most important prognostic factor. Radiotherapy might reduce the recurrence rate and improve overall survival.
Opinions on this matter vary, since it is difficult to determine the adequate dose of radiation for such a vast retroperitoneal space while avoiding postradiation complications and damage to vital organs. Intraoperative brachytherapy might allow use of an adequate radiation dose in places where recurrence is most likely while minimizing toxicity to other organs (16, 17) . Sindelar et al. (19) demonstrated a reduction in local recurrence from 80 to 40%, after combining intra-operative radiotherapy with postoperative adjuvant radiotherapy. This intraoperative boost increased the total radiation dose to 60 Gy.
Consecutive publications described either retrospective analyses or case reports of treatment of patients with retroperitoneal sarcomas. Bobin et al. (14) demonstrated promising results using combined intra-operative brachytherapy and postoperative radiotherapy: the five-year survival was 56%, with 28% asymptomatic survival.
Jones et al. (18) described the initial results of neoadjuvant radiotherapy supplemented by intra-operative brachytherapy. The two-year most important factor for treatment of patients with retroperitoneal sarcomas. We asked whether adjuvant therapy (radiotherapy, brachytherapy) was also beneficial"?
The comparison between total patient survival following radical operations without adjuvant radiotherapy (group I) with the survival following adjuvant therapy after the primary (group II) and secondary operations (group III) demonstrated statistically insignificant differences (p=0.440) that tended to favor adjuvant therapy ( fig. 3) . Given the data available in the literature, we conclude that our results were probably influenced by the small sample size. These patients require further observation and analysis. (20) demonstrated that lack of adjuvant radiotherapy and significant tumor malignancy are important and independent factors for increased risk of local recurrence. Their study's analysis of 165 patients demonstrated that the risk of local failure decreased three-or four-fold in cases where patients underwent adjuvant radiotherapy, in comparison to those without.
Windham and Pisters (7) reviewed both the reported data on retroperitoneal sarcoma treatment and their own results, and concluded that there was no advantageous model of adjuvant therapy. They highlighted the importance of radical surgical resection. Intraoperative brachytherapy, intraoperative radiotherapy, and other methods should be used during clinical trials in specialized centers.
Dziewirski (17) evaluated intraoperative and perioperative brachytherapy in combination with postoperative teleradiotherapy in their study of a group of 56 patients with retroperitoneal sarcomas. Recurrence-free and total survival rates were 55% and 51%, respectively.
Consistent with other authors (3-8), we conclude that radical surgical resection is the
